• World Neurosurg · Aug 2023

    Outcome of Brain metastases treated with Gamma knife Stereotactic Radiosurgery (GKSR): Cohort retrospective study on 205 cases.

    • BankoleNourou Dine AdeniranNDAGamma Knife Radiosurgery Unit, National Center for Rehabilitation and Neuroscience, Mohamed V University of Rabat, Rabat, Morocco. Electronic address: bankolenouroudine@yahoo.fr., Adyl Melhaoui, Yasser Arkha, Semmar Afaf, Khalid Bouyakhlef, Mahjouba Boutarbouch, Mohamed Jiddane, and Abdeslam El Khamlichi.
    • Gamma Knife Radiosurgery Unit, National Center for Rehabilitation and Neuroscience, Mohamed V University of Rabat, Rabat, Morocco. Electronic address: bankolenouroudine@yahoo.fr.
    • World Neurosurg. 2023 Aug 1; 176: e462e475e462-e475.

    BackgroundBrain metastases (BMs) are the most common expansive intracranial lesions in adults. Approximately 50% of patients diagnosed with new BMs will have >1 BM at the diagnosis. We report our experience with BMs treated with Leksell Gamma Knife stereotactic radiosurgery (GKSR) and evaluate the outcomes.MethodsPatients treated by GKSR in our institution between 2008 and 2021 for BMs were evaluated retrospectively.ResultsA total of 205 patients (56.6% women) were included, with a median age of 59 years (range, 25-83 years). The breast (n = 85; 42.5%) and lung (n = 76; 38%) were the most common original locations for the primary tumors. Of the 205 patients, 103 (50.3%) had a single BM and 102 (49.7%) had ≥2 BMs. The median number of multiple BMs treated was 4 (range, 2-43). The mean overall survival (OS) time was 6.00 months (95% confidence interval [CI], 5.07-6.93 months) for all BMs. The median rate of tumor control after radiosurgery was 65% (range, 20%-99%) during a median follow-up of 6.00 months (95% CI, 3-84 months). In the overall population, the 1-, 2-, and 5-year OS rate was 37.55%, 25.12%, and 18.51%, respectively. The mean OS time was longer for those with multiple BMs than for those with a single BM (mean, 10 months [95% CI, 6.67-13.33 months] vs. mean, 5 months [95% CI, 4.21-5.70 months]; P = 0.03). Retreatment, tumor stability (control), and progression influenced the OS of patients with BMs, whether single or multiple (P < 0.001).ConclusionsGKSR provides good results in terms of OS and better quality of life for patients with BMs, whether single or multiple. Tumor stability and retreatment influenced the OS of patients with BMs.Copyright © 2023 Elsevier Inc. All rights reserved.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.